Kamada inaugurates new rabies testing lab in Israel
The FDA-approved lab is one of few worldwide capable of rabies virus neutralization testing.
See the latest news and media coverage for Kamada. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global specialty plasma-derived biopharmaceutical company
kamada.comLast updated
In short: Kamada reported Q1 2026 revenue growth, affirmed its annual guidance, and secured FDA approval for a new rabies testing laboratory.
The FDA-approved lab is one of few worldwide capable of rabies virus neutralization testing.
Revenue rose 3% to $45.2 million, adjusted EBITDA was $11.6 million, and net income increased 4% to $4.1 million.
The center can collect 50,000 liters annually and generate an estimated US$8-10 million in revenue. It is one of the largest specialty plasma centers and will seek EMA approval.
The dividend is part of an annual policy to distribute at least 50% of net income, payable on April 6, 2026.
Kamada ( (IL:KMDA)) has shared an announcement. On January 7, 2026, Kamada issued 2026 financial guidance projecting revenues of $200 million to $205 million and...
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader...
Kamada (KMDA) earnings outlook covers AI demand, revenue acceleration, and growth forecasts with daily analyst insights and growth expectations. Kamada Ltd. (KMDA) reported earnings per...
Kamada Ltd. (NASDAQ:NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ETCompany ParticipantsBrian Ritchie - Investor Relations,...
Track Kamada and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kamada and other trending companies.